EMA Authorised: Epruvy (previously Ranibizumab Midas) (ranibizumab) — Midas Pharma GmbH

View source ↗

Summary

Epruvy, a new marketed form of ranibizumab by Midas Pharma, has been authorised for treating wet age-related macular degeneration, macular edema, choroidal neov…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Macular Edema
• Wet Age-related Macular Degeneration

Drugs mentioned

• Epruvy (ranibizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Choroidal Neovascularization;Diabetes Complications. MAH: Midas Pharma GmbH. Decision date: 13/11/2025